Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line
EORTC-PAMM Winter Meeting, Verona, Italy, 8th February 2019
Selected Oral presentation: “Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line”
By Dr. Alessandro Leonetti
The results of this study have been published in Biochemical Pharmacology:
www.ncbi.nlm.nih.gov/pubmed/31078602
PDF file: Decrease in p-PRAS40 plays a role in the synergy between erlotinib and crizotinib
